Early results show promise of CAR-T cell therapy for treating rare blood cancer
Eight of 11 patients (72.7%) treated in a early stage international clinical trial of a new drug for a rare form of blood cancer achieved complete remission, meaning there were no signs of cancer after treatment, a new study shows.
Newly approved myeloma treatment found highly effective in first real-world patient population
In a first test of more typical patients with multiple myeloma, a newly FDA-approved drug proved nearly as effective as in clinical trial
Stanford study offers hope to CAR T-cell therapy relapsed B cell lymphoma patients
In a small study, half of the patients whose lymphoma failed to respond to all previous treatments including CAR T-cell therapy, responded
FDA approves first T cell therapy for melanoma
CANCER DIGEST – Feb. 16, 2024 – The FDA today has approved a new T-cell therapy for the treatment of melanoma. The therapy called...
